Antheia, the revolutionary pharmaceutical ingredient manufacturer, is proud to announce the appointment of John Nicols to its Board of Directors. Joining the esteemed Board alongside co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang, Nicols’ expertise and experience in the industry will be a valuable asset to the company as it continues to transform supply chains for the better.
Nicols is thrilled to join the Antheia Board as its Chair and looks forward to working with such an impressive team. She is passionate about Antheia’s mission to build more resilient processes for biomanufacturing essential medicines, which will be transformative to the pharmaceutical industry and future-proof pharmaceutical supply chains.
Brian Nicols is an experienced business leader and value creator with more than three decades of experience in global businesses across biotechnologies and traditional chemistry. He has a strong track record of driving sustained growth and delivering impressive results.
As the former president and CEO of Codexis, he successfully led the transformation of the company into one of the leading synthetic biology companies and grew its product sales nine-fold to exceed $100 million.
Prior to Codexis, Nicols held various executive roles at Albemarle Corp, where he grew their largest business unit to more than $1 billion in global sales. He earned a M.B.A. from the Massachusetts Institute of Technology and a B.S. degree in chemical engineering from the Polytechnic Institute of New York University (now part of New York University).
We are delighted to announce that John has joined Antheia’s Board of Directors at a pivotal point in our company’s growth. His esteemed expertise in building biotech companies from R&D to commercial scale operations is an invaluable asset as we strive to introduce our advanced key starting materials (KSMs) and active pharmaceutical ingredients (APIs) to the marketplace.
Dr. Christina Smolke, co-founder and CEO of Antheia, expressed her excitement for John’s appointment, saying, “John is one of the most renowned leaders in the industry and we are thrilled to have him on board.”
Antheia is revolutionizing the pharmaceutical industry with their innovative approach to KSM (key starting materials) and API (active pharmaceutical ingredients) manufacturing. Through the power of synthetic biology, Antheia’s platform enables pharmaceutical companies to take control of their supply chains, preventing harmful drug shortages and providing an agile, resilient, and scalable method for biomanufacturing essential medicines. Located in Menlo Park, California, the team of scientists and technologists at Antheia are paving the way for a more secure and efficient healthcare system.